Wei Li, MD, PhD
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China;
Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China
Research interest: treatment of urinary system tumors, especially the surgery and immunotherapy of kidney cancer and prostate cancer, urinary tumor and translational medicine
Wei Li was a visiting scholar at the Wake Forest Institute of Regenerative Medicine of Wake Forest University in the United States, and a postdoctoral fellow at the Massachusetts General Hospital and the Dana-Farber Cancer Research Center affiliated to Harvard University.
Dr. Wei is a member of the Cancer Targeted Therapy Branch of the Chinese Society of Biomedical Engineering, also member of the American Cancer Society, Youth Member of the Translational Medicine Branch of the Chinese Overseas Student Physician Association of the European and American Student Association, New Star of Shanghai Medical Association, Pujiang talents, Outstanding Youth Fund of Tongji University. The research direction focuses on the role and regulation mechanism of small RNA in urinary system tumors, especially non-coding RNA in tumor invasion, metastasis and drug resistance. Developed small RNA drug interference targets to treat renal cell carcinoma.
Editorial Board
Terms of Appointment: September 2021 - August 2022